沙美特罗氟替卡松联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的疗效观察

Clinical observation of salmeterol fluticasone propionate combination Montelukast in treatment of children cough variant asthma

目的探讨沙美特罗氟替卡松联合孟鲁司特钠治疗儿童咳嗽变异性哮喘的疗效。方法将80例CVA患儿随机分为观察组和对照组各40例，对照组给予沙美特罗氟替卡松吸入剂2次／天，1吸／次，观察组在对照组的基础上给予孟鲁司特钠口服，4～5岁，每次4mg；6～14岁，每次5mg，每晚1次，共12周。观察两组患儿咳嗽缓解及消失时间，肺功能指标FEV1变化，及随访1年咳嗽复发率。结果观察组治疗疗效优于对照组，肺功能较对照组明显改善，两组比较差异有统计学意义（P〈0．05）。观察组复发率低于对照组，两组比较差异有统计学意义（P〈0．05）。结论沙美特罗氟替卡松联合孟鲁司特钠治疗CVA疗效优于单纯吸入沙美特罗氟替卡松，不良反应少且轻微，用药安全、方便，可作为儿童CVA治疗的一线选择。

objective To compare the effectiveness of salmeterol fluticasone propionate combination Montelukast in treatment of children cough variant asthma. Methods 80 children patients with CVA were randomly divided into tow groups, one was observation group （ n=40 ）, the other was control group （ n=40 ）. The control group were preformed with salmeterol fluticasone prapionate, l/time for inhalation twice daily, on this basis,＇ the observation group were preformed with Montelukast orally, 4 mg for 4 - 5 years old and 5 mg for 6 - 14 years old , all per os every night for a treatment course of 12 weeks. The cough relief time and cough disappearanee time were observed, FEV1 index of pulmonary fimction was observed. Followed-up 1 year was done to obtain the recurrence rate of cough. Results The therapy effect in the observation group was higher than the control group, and pulmonary function in the observation group have improved, there was a significant difference （P 〈 0.05）. The recurrence rate in the observation group was lower than the control group, there was a significant difference （P 〈 0.05）. Conclusions Salmeterol fluticasone propionate combination Montelakast is better than salmeterol fluticasone propionate alone in the treatment of cough variant asthma. Less adverse reaction and mild, medication is safety and convenience. It can be used as a treatment of children CVA line selection.